Marker Therapeutics, Inc.
MRKR
$1.10
-$0.10-8.33%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 79.04% | -0.75% | -12.23% | -5.76% | -24.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 79.04% | -0.75% | -12.23% | -5.76% | -24.58% |
| Cost of Revenue | 10.19% | -16.97% | -20.37% | -33.75% | -53.70% |
| Gross Profit | 19.59% | 24.80% | 24.08% | 41.81% | 60.33% |
| SG&A Expenses | -40.48% | -46.00% | -35.71% | -36.20% | -41.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.90% | -30.11% | -27.38% | -34.80% | -48.93% |
| Operating Income | 30.56% | 36.48% | 30.48% | 39.06% | 52.10% |
| Income Before Tax | 32.89% | 39.72% | 33.01% | 41.28% | 53.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 32.86% | 39.70% | 32.99% | 41.26% | 53.16% |
| Earnings from Discontinued Operations | -101.24% | -101.63% | 196.92% | 196.54% | 197.21% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.38% | 21.60% | 77.34% | 72.48% | 74.08% |
| EBIT | 30.56% | 36.48% | 30.48% | 39.06% | 52.10% |
| EBITDA | 80.58% | 66.21% | 47.71% | 45.36% | 58.97% |
| EPS Basic | -0.61% | 25.70% | 78.54% | 73.88% | 74.84% |
| Normalized Basic EPS | 33.99% | 41.54% | 35.65% | 43.78% | 55.28% |
| EPS Diluted | -0.64% | 25.66% | 78.35% | 73.77% | 74.86% |
| Normalized Diluted EPS | 33.99% | 41.54% | 35.65% | 43.78% | 55.28% |
| Average Basic Shares Outstanding | 2.63% | 3.75% | 4.74% | 5.49% | 4.12% |
| Average Diluted Shares Outstanding | 2.63% | 3.75% | 4.74% | 5.49% | 4.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
